FDA Says Shandong Vianor Biotech Falsified Data And Impeded Inspection
FDA warning letter says Shandong Vianor Biotech in China falsified test results and barred an investigator from entering a laboratory during an inspection of the firm’s facility in May.
You may also be interested in...
Agency should clarify how quickly it expects requested documents to be produced before a company is determined to have delayed an inspection, attorneys say during a FDLI meeting discussion of how a 2012 law enabling the agency to put a foreign facility on import alert for delaying, limiting, or refusing an inspection has played out.
FDA warning letter says Foshan Flying Medical Products needs to hire more people in quality control and improve its sterility testing; EU GMP noncompliance notice goes to Bristol Labs in the UK for data integrity flaws; FDA hits six firms with drug GMP import alerts.
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”